Arrowhead to Present at Upcoming Conferences

  Arrowhead to Present at Upcoming Conferences

AASLD Annual Meeting 2013 International Meeting on Molecular Biology of
Hepatitis B Viruses 2013

Business Wire

PASADENA, Calif. -- October 18, 2013

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced that it will present
data on ARC-520, its hepatitis B drug candidate, at two upcoming scientific
conferences.

Scheduled conference presentations include the following:

2013 International Meeting on Molecular Biology of Hepatitis B Viruses -
Shangai, China, October 20-23, 2013

October 23, 2013 – A poster presentation titled, “Kinetics of knockdown from
RNAi therapeutic ARC-520 on hepatitis B virus RNA, DNA, S antigen and e
antigen in mice and chimpanzee,” will be presented by Christine Wooddell,
Ph.D., Senior Scientist;

AASLD – The Liver Meeting - Washington, DC, USA, November 1-5, 2013

November 3, 2013 – A poster presentation titled, “ARC-520 RNAi therapeutic
reduces HBV DNA, S and e antigen in a chimpanzee,” will be presented by Robert
E. Lanford, Ph.D., Texas Biomedical Research Institute.

About ARC-520

Approximately 350 million people worldwide are chronically infected with the
hepatitis B virus. Chronic HBV infection can lead to cirrhosis of the liver
and is responsible for 80% of primary liver cancers globally. Arrowhead’s
RNAi-based candidate ARC-520 is designed to treat chronic HBV infection by
reducing the expression and release of new viral particles and key viral
proteins. The goal is to achieve a functional cure, which is an immune
clearant state characterized by hepatitis B s-antigen negative serum with or
without sero-conversion. The siRNAs in ARC-520 intervene at the mRNA level,
upstream of where nucleotide and nucleoside analogues act. In transient and
transgenic mouse models of HBV infection, a single co-injection of Arrowhead’s
DPC delivery vehicle with cholesterol-conjugated siRNA targeting HBV sequences
resulted in multi-log knockdown of HBV RNA, proteins and viral DNA with long
duration of effect. In a chimpanzee chronically infected with HBV and high
viremia and antigenemia, ARC-520 induced rapid reductions of 90-95% in HBV
DNA, e-antigen, and s-antigen. Arrowhead has completed enrollment in a phase 1
single ascending dose study in normal volunteers, which the company expects to
follow with a phase 2a study in chronic HBV patients.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and obesity and partner-based programs in oncology.

For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to ir@arrowres.com.

Contact:

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
or
The Trout Group
Lauren Glaser
646-378-2972
ir@arrowres.com
 
Press spacebar to pause and continue. Press esc to stop.